Affiris Develops Alzheimer's Vaccine

The Viennese biotech company Affiris is taking stock of the progress achieved to date in its clinical Alzheimer's vaccination programme. All the Alzheimer's patients treated so far as part of the toxicological trials have tolerated the treatment extremely well. As a result, Affiris is among the leading international centres in the race to develop the first causal immunotherapy for Alzheimer's disease.

Added: 30 апреля 2008

Last relative articles:

Comments: [0] / Post comment:

28 Dec 2008 17:16:25

Alfred Wieder AG (AWAG) wдchst dem Trend in der Finanzbranche zum ... - BSOZD.com - News (Pressemitteilung)

Alfred Wieder AG (AWAG) wдchst dem Trend in der Finanzbranche zum ... BSOZD.com - News (Pressemitteilung), Germany - Eines der prominentesten Lead Investments des Fonds ist die Affiris GmbH aus Wien. Das Biotechnologieunternehmen hatte durch eine Vereinbarung mit dem ...

Source: http://bsozd.com/

23 Dec 2008 19:17:48

52 Millionen Euro fьr Vienna Biocenter - Die Presse

52 Millionen Euro fьr Vienna Biocenter Die Presse, Austria - ... und Institute der Uni Wien entwickelt. Es ist heute auch Heimat von Forschungsinstituten der ЦAW und von Biotech-Firmen wie Intercell oder Affiris . red.

Source: http://diepresse.com/home/techscience/wissenschaft/440008/in~.do

19 Dec 2008 07:11:21

[] M&A- -

M&A- , South Korea - ... (Valeant) 3 82000, ( Affiris ) 55300, BMS 2 ...

Source: http://bosa.co.kr/special/view.asp

17 Dec 2008 21:07:49

GlaxoSmithKline, Dynavax agree to $800M drug development deal - Bizjournals.com

GlaxoSmithKline, Dynavax agree to $800M drug development deal Bizjournals.com, NC - ... a drug development deal for Alzheimers treatments with Austrian company Affiris GmbH that could total $550 million, and the $170 million purchase of ...

Source: http://bizjournals.com/philadelphia/stories/2008/12/15/daily~.html

16 Dec 2008 17:18:15

Alfred Wieder AG: Fьr die AWAG ist 2008 ein Rekordjahr - PRESSESCHLEUDER (Pressemitteilung)

Alfred Wieder AG: Fьr die AWAG ist 2008 ein Rekordjahr PRESSESCHLEUDER (Pressemitteilung), Germany - Die Affiris GmbH aus Wien ist eines der prominentesten Lead Investments des Fonds. Das Biotechnologieunternehmen hatte durch eine Vereinbarung mit dem ...

Source: http://presseschleuder.com/2008/12/16/alfred-wieder-ag-fur-d~

12 Dec 2008 14:08:29

AFFiRiS Develops Parkinson's Vaccine - eMaxHealth.com

AFFiRiS Develops Parkinson's Vaccine eMaxHealth.com, NC - AFFiRiS has started pre-clinical development of a Parkinson's vaccine. The vaccine, known as PD01, can be used to target a specific protein that is closely ...

Source: http://emaxhealth.com/2/95/27487/affiris-develops-parkinson-~.html

Keywords:

affiris, affiris develops, vaccine affiris, affiris taking, affiris leading, company affiris, result affiris

ALL NEWS TODAY